BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35799398)

  • 1. [A Case of Advanced Adenocarcinoma at the Esophagogastric Junction That Exhibited pCR by Preoperative SOX Therapy].
    Mihara D; Kuwada K; Hamazaki T; Namba K; Takahashi T; Takehara K; Kuise T; Kuroda M; Yamano T; Takagi S; Ikeda E; Kemmotsu M; Ikeda T
    Gan To Kagaku Ryoho; 2022 Jun; 49(6):693-696. PubMed ID: 35799398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A Case of cStage Ⅲ Esophagogastric Junction Adenocarcinoma That Showed pCR to Preoperative Chemotherapy Containing SOX].
    Kobayashi T; Kosuga T; Kubota T; Okamoto K; Shoda K; Konishi H; Shiozaki A; Fujiwara H; Arita T; Morimura R; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Otsuji E
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):2369-2371. PubMed ID: 30692467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
    Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
    BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
    Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction.
    Hosoda K; Azuma M; Katada C; Ishido K; Niihara M; Ushiku H; Sakuraya M; Washio M; Wada T; Watanabe A; Harada H; Tanabe S; Koizumi W; Yamashita K; Hiki N
    Int J Clin Oncol; 2020 Jun; 25(6):1090-1097. PubMed ID: 32124094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant docetaxel, oxaliplatin and S‑1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction.
    Saito T; Kurokawa Y; Takahashi T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Nakajima K; Eguchi H; Doki Y
    Gastric Cancer; 2022 Sep; 25(5):966-972. PubMed ID: 35488968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Six Cases of Esophagogastric Junctional Cancer Successfully Treated with Neoadjuvant Chemotherapy].
    Hiroi S; Fukuda S; Yamahata Y; Otani T; Tada T; Hirukawa H
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1685-1687. PubMed ID: 38303173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 10. [A Case of Advanced Esophagogastric Junction Adenocarcinoma with Enlarged Lymph Node Metastases of the Middle Mediastinum and Intraperitoneal That Exhibited pCR by Preoperative SOX Therapy].
    Mita K; Oda H; Sato M; Takahashi K; Shimaguchi M; Kobayashi N; Kouno M; Toyota T; Toyota N; Hatano M; Sasaki J; Kawamura Y; Nishida K
    Gan To Kagaku Ryoho; 2023 Aug; 50(8):909-912. PubMed ID: 37608419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
    Briasoulis E; Fatouros M; Roukos DH
    Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806
    [No Abstract]   [Full Text] [Related]  

  • 12. Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial.
    Yoshikawa T; Aoyama T; Tanabe K; Nishikawa K; Ito Y; Hayashi T; Cho H; Miyashita Y; Tsuburaya A; Sakamoto J
    Dig Surg; 2016; 33(5):424-30. PubMed ID: 27164988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
    Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
    Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
    Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
    Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial.
    Jiang Z; Xie Y; Zhang W; Du C; Zhong Y; Zhu Y; Jiang L; Dou L; Shao K; Sun Y; Xue Q; Tian Y; Gao S; Zhao D; Zhou A
    Gastric Cancer; 2024 May; 27(3):571-579. PubMed ID: 38457083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surgical strategy for adenocarcinoma of esophagogastric junction].
    Lu Y; Zhang K; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):107-111. PubMed ID: 30799532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Three Cases of Adenocarcinoma of the Advanced Esophago-Gastric Junction Confirmed as Pathological Complete Response Following Neoadjuvant Chemotherapyand Gastrectomy].
    Sato T; Maezawa Y; Kano K; Segami K; Nakajima T; Ikeda K; Aoyama T; Hayashi T; Yamada T; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1561-1563. PubMed ID: 28133057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized surgical strategies for cancer of the esophagogastric junction.
    Stein HJ; Feith M; Siewert JR
    Ann Chir Gynaecol; 2000; 89(3):191-8. PubMed ID: 11079787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
    Yang S; Yuan Y; Hu H; Li R; Liu K; Zhang W; Yang K; Yang Y; Bai D; Chen X; Zhou Z; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):132-142. PubMed ID: 30799535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study).
    Tokunaga M; Machida N; Mizusawa J; Ito S; Yabusaki H; Hirao M; Watanabe M; Imamura H; Kinoshita T; Yasuda T; Hihara J; Fukuda H; Yoshikawa T; Boku N; Terashima M
    Gastric Cancer; 2024 May; 27(3):580-589. PubMed ID: 38243037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.